Product-Specific or Class-Specific Biosimilar Guidances? US FDA Wants Feedback

 
• By Sarah Karlin-Smith
  
monoclonal antibdoy
Biosimilar sponsors have 90 days to suggest the type of guidance that would be most helpful from the FDA. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics